The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
BSR and BHPR guidelines for the management of polymyalgia rheumatica
Open accessAbstract
PMR is the most common inflammatory rheumatic disease in the elderly and is one of the biggest indications for long-term steroid therapy. There are difficulties in diagnosis, with heterogeneity in presentation, response to steroids and disease course. The aim of these guidelines is a safe and specific diagnostic process for PMR, using continued assessment, and discouragement of hasty initial treatment. Their scope is to provide advice for the diagnosis of PMR, management and monitoring of disease activity, complications and relapse. The management of GCA is not covered and is published separately. The full guideline is available at Rheumatology online. (1) We recommend that a safe, stepped diagnostic process be adopted for the evaluation of PMR (Strength of recommendation C). Diagnosis of PMR should start with evaluation of core inclusion and exclusion criteria, followed by assessment of the response to a standardized dose of steroid [1]. Atypical features or response to steroid should prompt consideration of alternative pathology, and specialist referral. Unlike with GCA, urgent institution of steroid therapy is not necessary and can be delayed to allow full assessment. However, if the patient does present with symptoms suspicious of GCA, then urgent institution of high-dose steroid therapy is needed (see Guidelines for Management of GCA). (i) Core inclusion criteria: PMR can be diagnosed with normal inflammatory markers, if there is a classic clinical picture and response to steroids. These patients should be referred for specialist assessment. Age >50 years, duration >2 weeks Bilateral shoulder or pelvic girdle aching, or both Morning stiffness duration of >45 min Evidence of an acute-phase response (ii) Core exclusion criteria: Active infection Active cancer Active GCA (see part iii) The presence of the following conditions decreases the probability of PMR, and they should also be excluded: Other inflammatory rheumatic diseases Drug-induced myalgia Chronic pain syndromes Endocrine disease Neurological conditions, e.g. Parkinsons disease (iii) Patients should be assessed for evidence of GCA, as this requires urgent institution of high-dose steroid (see separate guidelines) Abrupt-onset headache (usually temporal) and temporal tenderness Visual disturbance, including diplopia Jaw or tongue claudication Prominence, beading or diminished pulse on examination of the temporal artery Upper cranial nerve palsies Limb claudication or other evidence of large-vessel involvement (iv) Patients should be assessed for response to an initial standardized dose of prednisolone 15 mg daily orally [1, 2]. A patient-reported global improvement of ⩾70% within a week of commencing steroids is consistent with PMR, with normalization of inflammatory markers in 4 weeks. A lesser response should prompt the search for an alternative condition. (v) The diagnosis of PMR should be confirmed on further follow-up [2]. Follow-up visits should include vigilance for mimicking conditions. (2) We recommend documentation in the patient's medical record of a minimum data set, which forms the basis for the diagnosis. The core clinical inclusion and any exclusion criteria Laboratory investigations before commencement of steroid therapy Full blood count ESR/plasma viscosity and/or CRP Urea and electrolytes Liver function tests Bone profile Protein electrophoresis (also consider urinary Bence Jones Protein) Thyroid stimulating hormone Creatine kinase RF (ANA and anti-CCP antibodies may be considered) Dipstick urinalysis Chest X-ray may be required (3) We recommend the following approach for the evaluation of proximal pain and stiffness [3] (Fig. 1). (4) We recommend early specialist referral in the following circumstances (C). Atypical features or features that increase likelihood of a non-PMR diagnosis: Age <60 years Chronic onset (>2 months) Lack of shoulder involvement Lack of inflammatory stiffness Prominent systemic features, weight loss, night pain, neurological signs Features of other rheumatic disease Normal or extremely high acute-phase response Treatment dilemmas such as: However, patients with a typical clinical picture and complete sustained response to treatment, and no adverse events can be managed in primary care. Incomplete, poorly sustained or non-response to corticosteroids Inability to reduce corticosteroids Contraindications to corticosteroid therapy The need for prolonged corticosteroid therapy (>2 years) Approach to the evaluation of proximal pain and stiffness. ACJ: acromio-clavicular joint. (5) We recommend initiation of low-dose steroid therapy with gradually tailored tapering in straightforward PMR (B). In the absence of GCA, urgent steroid therapy is not indicated before the clinical evaluation is complete. The suggested regimen is: However, there is no consistent evidence for an ideal steroid regimen suitable for all patients. Therefore, the approach to treatment must be flexible and tailored to the individual as there
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Walsh, L. J., Wong, C. A., Pringle, M., & Tattersfield, A. E. (1996) · BMJ · doi:10.1136/bmj.313.7053.344 · Cited by 383
Cited by
Dasgupta, B., Cimmino, M. A., Maradit-Kremers, H., Schmidt, W. A., Schirmer, M., Salvarani, C., Bachta, A., Dejaco, C., Duftner, C., Jensen, H. S., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200329 · Cited by 673
Self-citationPolymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review
Buttgereit, F., Dejaco, C., Matteson, E. L., & Dasgupta, B. (2016) · JAMA · doi:10.1001/jama.2016.5444 · Cited by 496
Self-citationDasgupta, B., Cimmino, M. A., Kremers, H. M., Schmidt, W. A., Schirmer, M., Salvarani, C., Bachta, A., Dejaco, C., Duftner, C., Jensen, H. S., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34356 · Cited by 413
Self-citationGiant-Cell Arteritis and Polymyalgia Rheumatica
Weyand, C. M., & Goronzy, J. J. (2014) · New England Journal of Medicine · doi:10.1056/nejmcp1214825 · Cited by 410
Dejaco, C., Duftner, C., Buttgereit, F., Matteson, E. L., & Dasgupta, B. (2016) · Rheumatology · doi:10.1093/rheumatology/kew273 · Cited by 365
Self-citation
Metadata
- Authors
- Dasgupta, B., Borg, F. A., Hassan, N., Barraclough, K., Bourke, B., Fulcher, J., Hollywood, J., Hutchings, A., Kyle, V., Nott, J., Power, M., Samanta, A., & on behalf of the BSR and BHPR Standards, G. A. A. W. G.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-11-12
- Volume
- 49
- Issue
- 1
- Pages
- 186-190
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2128783050
- Cited by
- 251
- References
- 1
- FWCI
- 11.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BSR and BHPR guidelines for the management of polymyalgia rheumatica. https://app.cochat.ai/papers/10.1093/rheumatology/kep303a
- The paper
- Dasgupta, B., Borg, F. A., Hassan, N., Barraclough, K., Bourke, B., Fulcher, J., Hollywood, J., Hutchings, A., Kyle, V., Nott, J., Power, M., Samanta, A., & on behalf of the BSR and BHPR Standards, G. A. A. W. G. (2010). BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology. https://doi.org/10.1093/rheumatology/kep303a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.